

# A cryptic imatinib-sensitive *G3BP1-PDGFRB* rearrangement in a myeloid neoplasm with eosinophilia

Max Jan,<sup>1,2</sup> Daniel E. Grinshpun,<sup>2,3</sup> Julian A. Villalba,<sup>1</sup> Paola Dal Cin,<sup>4,5</sup> David B. Sykes,<sup>4,6</sup> A. John Iafrate,<sup>1,4</sup> Benjamin L. Ebert,<sup>2,4,7</sup> Gabriela S. Hobbs,<sup>4,8</sup> and Valentina Nardi<sup>1,4</sup>

<sup>1</sup>Department of Pathology, Massachusetts General Hospital, Boston, MA; <sup>2</sup>Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA; <sup>3</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; <sup>4</sup>Harvard Medical School, Harvard University, Boston, MA; <sup>5</sup>Department of Pathology, Brigham and Women's Hospital, Boston, MA; <sup>6</sup>Division of Hematology, Massachusetts General Hospital Cancer Center, Boston, MA; <sup>7</sup>Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA; and <sup>8</sup>Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA

## Key Points

- Targeted RNA sequencing detected a cryptic *G3BP1-PDGFRB* rearrangement in a myeloid neoplasm with eosinophilia and normal FISH studies.
- Consistent with the patient's response to imatinib, we demonstrate this rearrangement is oncogenic and sensitive to TKI in cell culture.

## Introduction

Cytogenetic or molecular detection of an oncogenic driver rearrangement is required for the World Health Organization diagnosis of "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of *PDGFRA*, *PDGFRB*, *FGFR1*, or with *PCM1-JAK2*." High rates of durable responses to imatinib therapy have changed the natural history of *PDGFRA*- and *PDGFRB*-rearranged myeloid neoplasms<sup>1,2</sup>; however, the molecular heterogeneity of the rearrangements can be a diagnostic challenge. *ETV6* was the first *PDGFRB* fusion partner to be discovered and remains the most common recurrent translocation t(5;12)(q32;p13.2).<sup>3,4</sup> Subsequently, 5' partner genes with oligomerization domains have been shown to rearrange with the 3' region of *PDGFRB* encoding the kinase domain to form constitutively active tyrosine kinase fusion oncoproteins. Given that >30 diverse genes have been identified in rearrangements with *PDGFRB*,<sup>4-7</sup> standard cytogenetic and molecular methods may not identify all actionable *PDGFRB* fusions. Here, we present a case of a patient with a myeloid neoplasm with eosinophilia (MLN-EO) and a novel cryptic rearrangement involving exons 12 to 23 of *PDGFRB* at 5q32 and the 5' (UTR) of *G3BP1* at 5q33.1, which is also undetectable by *PDGFRB* break-apart fluorescence in situ hybridization (FISH). In a cell culture model, we showed that the fusion is oncogenic and sensitive to tyrosine kinase inhibition. The patient had a dramatic response to imatinib that was persistent at 16 months but has not achieved molecular remission.

## Case description

A 22-year-old man with a history of childhood giant cell hepatitis, on therapy for the past 5 years with azathioprine, and a family history only notable for celiac disease in the mother, was referred for evaluation of hypereosinophilia in the setting of anemia and thrombocytopenia (white blood cell count,  $9.83 \times 10^9/L$ ; 27.9% eosinophils; absolute eosinophil count,  $2.74 \times 10^9/L$ ; hemoglobin, 11.9 g/dL; platelet count,  $69 \times 10^9/L$ ). Three months prior to referral, his complete blood cell was normal. His azathioprine was discontinued.


Although initially asymptomatic, the patient rapidly developed night sweats, abdominal pain, weight loss, malaise, and fatigue, and examination revealed tender splenomegaly that was palpable 10 cm below the left costal margin. A bone marrow biopsy revealed a markedly hypercellular marrow (~95% cellularity), with myeloid-predominant trilineage hematopoiesis, markedly increased eosinophilic forms (41% of cellularity), and no increase in blasts (Figure 1A-C). Many eosinophils appeared immature and showed uneven granulation. The findings were suggestive of an MLN-EO.

Conventional bone marrow cytogenetic analysis was notable for trisomy 8: 47,XY,+8[11]/46,XY[9] (Figure 1D). Interphase *PDGFRB* break-apart FISH did not identify a *PDGFRB* rearrangement. A targeted DNA-sequencing panel for genes recurrently mutated in hematologic malignancies did not reveal any putative driver mutations. However, a targeted RNA-sequencing panel for hematologic

Submitted 4 November 2019; accepted 16 December 2019; published online 30 January 2020. DOI 10.1182/bloodadvances.2019001182.

Cell culture sequences and reagents are available from Valentina Nardi (vnardi@partners.org). The targeted RNA sequencing reported here is clinical testing not for public deposition.

© 2020 by The American Society of Hematology



**Figure 1. Histologic, cytogenetic, and molecular characteristics of the MLN-EO and a *G3BP1-PDGFRB* fusion.** Hematoxylin and eosin–stained bone marrow core biopsy at low magnification ( $\times 4$ ) (A) and high magnification ( $\times 40$ ) (B), showing a hypercellular myeloid-predominant marrow with markedly increased eosinophilic forms. (C) May-Grünwald-Giemsa–stained bone marrow aspirate showing eosinophils in various stages of differentiation (magnification,  $\times 100$ ). (D) G-banding karyotype showing trisomy 8. (E) Schematic representation of the fusion transcript between the 5'UTR of *G3BP1* and exons 12 of *PDGFRB*, detected by targeted AMP sequencing off RNA.

malignancies identified chimeric fusion transcripts involving the 5'UTR of *G3BP1* (5') and exon 12 of *PDGFRB* (3') (Figure 1E).

The patient had a dramatic response to treatment with imatinib (400 mg/d), with rapid resolution of leukocytosis, eosinophilia, and splenomegaly; a 6-pound weight gain; and significant improvement in fatigue, loss of appetite, and night sweats. Although our heme fusion targeted RNA-sequencing assay is, in clinical practice, a qualitative assay for the presence or absence of fusion transcripts, *G3BP1-PDGFRB* fusion reads were markedly reduced, but still detected, upon repeat molecular testing after initiation of imatinib (Figure 2A). At the time of writing, the patient is in hematologic remission after 16 months of therapy.

## Methods

### Patient

The subject was treated per standard of care with imatinib.

### Karyotyping and FISH evaluation

G-banded karyotype was performed per standard procedures. FISH testing for *BCR-ABL1*, *PDGFRA*, and *PDGFRB* rearrangements (Abbott Vysis probes) was performed using a dual color–dual fusion probe, a 4q12 Tri-Color Rearrangement, and a break-apart probe, respectively.

### Molecular testing

Total nucleic acid isolated from bone marrow aspirate and peripheral blood specimens was subjected to targeted Illumina NextSeq next-generation sequencing using 2 clinically validated anchored multiplex polymerase chain reaction (AMP) assays.<sup>8</sup> 1 (heme SNaPshot) DNA based, to detect single nucleotide variants and insertions/deletions in 103 genes and the other one (heme fusion) RNA based, to detect fusion transcripts involving 82 genes.


### Cell culture and immunoblotting assays

Ba/F3 cells were maintained in media containing 10 ng/mL murine interleukin-3 (IL-3; PeproTech; catalog number 213-13). Transgenes were synthesized and cloned into a pSFFV–entry site–GFP-IRES-mCherry-pEF1-Puro lentivector. A CellTiter-Glo assay (Promega) was used, according to the manufacturer's instructions, to measure viability of Ba/F3 cells carrying the *ETV6-PDGFRB* or the *G3BP1-PDGFRB* fusion gene after 48 hours of exposure to tyrosine kinase inhibitor or vehicle control. The following antibodies were used for immunoblotting: phosphorylated STAT5 (4322S), STAT5 (94205S), phosphorylated AKT (4060S), AKT (4685S), GFP (2555S), and  $\beta$ -actin (3700S) (all from Cell Signaling Technologies).

## Results and discussion

The IL-3–dependent murine cell line Ba/F3 was transduced with lentivirus to express the *G3BP1-PDGFRB* fusion transcript, a truncated *PDGFRB* exon 12\_23 transcript, or the canonical oncogenic *ETV6* exon 1\_4-*PDGFRB* exon 11\_23 transcript (Figure 2B-C). When deprived of IL-3, only cells carrying *ETV6-PDGFRB* or *G3BP1-PDGFRB* constructs could outcompete nontransduced cells (Figure 2D) and maintain constitutive JAK/STAT pathway activation (Figure 2E). In this model, the 5'UTR of *G3BP1* was necessary to confer oncogenic properties to truncated *PDGFRB*. Compared with cells expressing the *ETV6-PDGFRB* fusion, cells expressing *G3BP1-PDGFRB* were more sensitive to treatment with imatinib and ponatinib and equally sensitive to treatment with dasatinib and bosutinib (Figure 2F).

Here, we describe a patient with clinicopathologic features consistent with an MLN-EO and a novel and cryptic *G3BP1-PDGFRB* rearrangement. The patient's disease rapidly improved after tyrosine kinase inhibition with imatinib. Karyotype and interphase FISH analysis failed to identify rearrangement of the *PDGFRB* gene (the 2 genes are  $< 2$  Mb apart and are joined through a paracentric inversion). However, Massachusetts General



**Figure 2. The novel oncogenic *G3BP1-PDGFRB* fusion protein responds to targeted inhibition.** (A) Treatment course of the index patient. The *G3BP1-PDGFRB* fusion transcript was detectable in all heme fusion targeted RNA-sequencing assays, albeit at lower levels, after initiation of imatinib. To normalize for sequencing depth across different assays, the *G3BP1-PDGFRB* transcript count was normalized to a highly expressed transcript, *PICALM*. (B) Schematic representation of the constructs used to overexpress fusion transcripts *ETV6-PDGFRB*, *G3BP1-PDGFRB*, and truncated *PDGFRB* (exons 12-23) in Ba/F3 cell lines. (C) GFP expression measured by flow cytometric analysis confirms overexpression of transduced *PDGFRB* constructs. Dark gray = untransduced. (D) Outgrowth of transduced cells over the indicated time frame, starting from 1% to 5% transduced cell populations. Black = empty vector. (E) Lysate of Ba/F3 cells with *G3BP1-PDGFRB*, *ETV6-PDGFRB*, or empty vector (mock) with or without IL-3. (F) Viability of Ba/F3 cells exposed to ranges of tyrosine kinase inhibitors assessed by CellTiter-Glo. Experiments were performed in triplicate. Error bars indicate standard deviation.

Hospital's clinically validated targeted RNA-sequencing assay identified a fusion transcript linking the *G3BP1* 5'UTR and *PDGFRB* exon 12. Cell culture studies confirmed that this fusion was oncogenic and sensitive to ABL1/PDGFRB kinase inhibition.

G3BP stress granule assembly factor 1 (*G3BP1*; also known as Ras-GTPase activating protein SH3 domain-binding protein 1) is an RNA-binding protein involved in the regulation of cellular functions, including stress granule formation, in response to extracellular stimuli, promotion of S-phase entry, regulation of cell apoptosis, and modulation of RAS signaling.<sup>9,10</sup> To our knowledge, this is the first

report of an MLN-EO linked to a genetic alteration involving *G3BP1*. In addition, the fusion does not involve the coding sequence of *G3BP1* but its 5'UTR. Fusions with UTRs, particularly 5'UTRs, are not commonly reported or characterized, although they have been described in ~5% of gene fusions based on a large study that included 33 cancer types.<sup>11</sup>

Multiple reports have detailed the successful and rapid clinical response to different doses of imatinib (100-400 mg/d) in patients with *PDGFRB*-rearranged MPN<sup>1,2,6,12</sup> leading to durable long-term remissions, a 6-year progression-free survival rate of 88% (95%

confidence interval, 65-97), and a 10-year overall survival rate of 90% (95% confidence interval, 64-97). Although reports are limited, all patients achieving hematologic response did so within 2 months of therapy initiation. In addition, all patients who achieved a molecular remission (36%) sustained this remission without the development of resistance and without the need to treat with second-generation tyrosine kinase inhibitors.<sup>6</sup> Insufficient data are available to evaluate the potential for imatinib withdrawal in this patient population. Indeed, imatinib discontinuation in patients with PDGFRA-rearranged MPN has been linked to rapid disease relapse.<sup>13,14</sup> Therefore, the patient, particularly in light of persistent molecular evidence of disease (Figure 2A), remains on treatment with imatinib.

In summary, these findings illuminate an unusual mode of proto-oncogene activation and highlight the importance of comprehensive morphologic, cytogenetic, and molecular diagnostic evaluation for patients with hypereosinophilia who may benefit from targeted therapy.

## Acknowledgments

The authors thank the patient and his family for their cooperation with this study.

This work was supported by National Institutes of Health, National Cancer Institute Project K-12-CA087723 (G.S.H.).

## References

1. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. *Blood*. 2017;129(6):704-714.
2. Jawhar M, Naumann N, Schwaab J, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. *Ann Hematol*. 2017;96(9):1463-1470.
3. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell*. 1994;77(2):307-316.
4. Keene P, Mendelow B, Pinto MR, et al. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association. *Br J Haematol*. 1987;67(1):25-31.
5. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. *Blood*. 1997;90(12):4947-4952.
6. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. *Blood*. 2014;123(23):3574-3577.
7. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. *Acta Haematol*. 2002;107(2):113-122.
8. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. *Nat Med*. 2014;20(12):1479-1484.
9. Duchesne M, Schweighoffer F, Parker F, et al. Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling. *Science*. 1993;259(5094):525-528.
10. Wang Y, Fu D, Chen Y, et al. G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas. *Cell Death Dis*. 2018;9(5):501.
11. Gao Q, Liang WW, Foltz SM, et al. Driver fusions and their implications in the development and treatment of human cancers. *Cell Rep*. 2018;23(1):227-238.e3.
12. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. *N Engl J Med*. 2002;347(7):481-487.
13. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. *Haematologica*. 2007;92(9):1173-1179.
14. Qu SQ, Qin TJ, Xu ZF, et al. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. *Oncotarget*. 2016;7(22):33229-33236.

## Authorship

Contribution: M.J., D.E.G., J.A.V., G.S.H., V.N., and D.B.S. wrote the manuscript; V.N., M.J., D.E.G., B.L.E., A.J.I., and P.D.C. designed the study, performed experiments, and interpreted data; G.S.H. and D.B.S. were responsible for patient care and provided clinical data; and all authors reviewed, edited, and approved the final manuscript.

Conflict-of-interest disclosure: A.J.I. has partial ownership in, and has acted as an advisor for, Archer Diagnostics. D.B.S. is a co-founder and holds equity in Clear Creek Bio. B.L.E. has received research funding from Celgene and Deerfield, has received consulting fees from GRAIL, and serves on the scientific advisory boards for Skyhawk Therapeutics and Exo Therapeutics. G.S.H. has received research funding through Bayer, Merck, and Incyte and has acted as a consultant for Incyte, Celgene, Agios, and Jazz Pharmaceuticals. The remaining authors declare no competing financial interests.

ORCID profiles: J.A.V., 0000-0001-9230-8747; D.B.S., 0000-0002-9788-0221; G.S.H., 0000-0002-0199-9333.

Correspondence: Valentina Nardi, Massachusetts General Hospital, MGH Pathology Service, Warren 219, 55 Fruit St, Boston, MA 02114; e-mail: vnardi@partners.org.